KR102209667B1 - 돌연변이-아이소시트레이트 탈수소효소 저해제로서의 피리딘-2(1h)-온 퀴놀린 유도체 - Google Patents

돌연변이-아이소시트레이트 탈수소효소 저해제로서의 피리딘-2(1h)-온 퀴놀린 유도체 Download PDF

Info

Publication number
KR102209667B1
KR102209667B1 KR1020177010585A KR20177010585A KR102209667B1 KR 102209667 B1 KR102209667 B1 KR 102209667B1 KR 1020177010585 A KR1020177010585 A KR 1020177010585A KR 20177010585 A KR20177010585 A KR 20177010585A KR 102209667 B1 KR102209667 B1 KR 102209667B1
Authority
KR
South Korea
Prior art keywords
oxo
chloro
methyl
amino
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177010585A
Other languages
English (en)
Korean (ko)
Other versions
KR20170063742A (ko
Inventor
수잔 애쉬웰
앤-마리 캠벨
저스틴 앤드류 카라벨라
알. 브루스 디볼드
안나 에릭슨
개리 구스타프손
주니어 데이비드 알. 랜시아
지안 린
웨이 루
종궈 왕
Original Assignee
포르마 세라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 포르마 세라퓨틱스 인크. filed Critical 포르마 세라퓨틱스 인크.
Publication of KR20170063742A publication Critical patent/KR20170063742A/ko
Application granted granted Critical
Publication of KR102209667B1 publication Critical patent/KR102209667B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020177010585A 2014-09-19 2015-09-18 돌연변이-아이소시트레이트 탈수소효소 저해제로서의 피리딘-2(1h)-온 퀴놀린 유도체 Active KR102209667B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462053006P 2014-09-19 2014-09-19
US62/053,006 2014-09-19
US201562128089P 2015-03-04 2015-03-04
US62/128,089 2015-03-04
US201562150812P 2015-04-21 2015-04-21
US62/150,812 2015-04-21
PCT/US2015/051055 WO2016044789A1 (en) 2014-09-19 2015-09-18 Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors

Publications (2)

Publication Number Publication Date
KR20170063742A KR20170063742A (ko) 2017-06-08
KR102209667B1 true KR102209667B1 (ko) 2021-01-29

Family

ID=54291606

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177010585A Active KR102209667B1 (ko) 2014-09-19 2015-09-18 돌연변이-아이소시트레이트 탈수소효소 저해제로서의 피리딘-2(1h)-온 퀴놀린 유도체

Country Status (37)

Country Link
US (8) US9834539B2 (enExample)
EP (4) EP4257131A3 (enExample)
JP (1) JP6648115B2 (enExample)
KR (1) KR102209667B1 (enExample)
CN (3) CN107001328B (enExample)
AU (3) AU2015317329B2 (enExample)
BR (1) BR112017005238B1 (enExample)
CA (1) CA2961817C (enExample)
CL (1) CL2017000658A1 (enExample)
CO (1) CO2017003241A2 (enExample)
CY (2) CY1121149T1 (enExample)
DK (2) DK3447050T3 (enExample)
EA (1) EA034336B1 (enExample)
EC (1) ECSP17022933A (enExample)
ES (3) ES2790640T3 (enExample)
FI (1) FI3733662T3 (enExample)
HR (1) HRP20200666T1 (enExample)
HU (2) HUE062424T2 (enExample)
IL (3) IL292608B2 (enExample)
LT (2) LT3447050T (enExample)
MA (2) MA53352A (enExample)
ME (1) ME03776B (enExample)
MX (2) MX2017003404A (enExample)
MY (2) MY176250A (enExample)
NZ (1) NZ730373A (enExample)
PE (1) PE20171056A1 (enExample)
PH (1) PH12017500517B1 (enExample)
PL (3) PL3194376T3 (enExample)
PT (3) PT3733662T (enExample)
RS (2) RS60140B1 (enExample)
SA (1) SA517381129B1 (enExample)
SG (1) SG11201702194SA (enExample)
SI (2) SI3194376T1 (enExample)
SM (2) SMT202000212T1 (enExample)
TW (1) TWI686390B (enExample)
WO (1) WO2016044789A1 (enExample)
ZA (3) ZA201702127B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2740424T3 (es) 2009-03-13 2020-02-05 Agios Pharmaceuticals Inc Métodos y composiciones para trastornos relacionados con la proliferación celular
EP3064595B1 (en) 2009-10-21 2019-02-27 Agios Pharmaceuticals, Inc. Methods for cell-proliferation-related disorders
EP3102568B1 (en) 2014-02-06 2018-06-27 Heptares Therapeutics Limited Bicyclic aza compounds as muscarinic m1 receptor agonists.
KR102209667B1 (ko) * 2014-09-19 2021-01-29 포르마 세라퓨틱스 인크. 돌연변이-아이소시트레이트 탈수소효소 저해제로서의 피리딘-2(1h)-온 퀴놀린 유도체
MX372964B (es) 2014-09-19 2020-03-27 Forma Therapeutics Inc Derivados de fenil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh)
MX2017003664A (es) 2014-09-19 2017-07-13 Bayer Pharma AG Indazoles sustituidos con benzilo como inhibidores de bub1.
EP3201185B1 (en) 2014-09-19 2018-11-21 Forma Therapeutics, Inc. Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
AU2015317321B2 (en) * 2014-09-19 2020-03-12 Forma Therapeutics, Inc. Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
CN107428690B (zh) * 2014-12-22 2021-04-13 美国政府健康及人类服务部 可用于治疗癌症的突变idh1抑制剂
US9624216B2 (en) 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
WO2016171755A1 (en) 2015-04-21 2016-10-27 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
HUE059057T2 (hu) 2017-05-04 2022-10-28 Bayer Cropscience Ag 2-{[2-(feniloximetil)piridin-5-il]oxi}-etánamin-származékok és rokon vegyületek mint peszticidek, például növényvédelemre
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
WO2020232381A1 (en) 2019-05-16 2020-11-19 Forma Therapeutics, Inc. INHIBITING MUTANT ISOCITRATE DEHYDROGENASE 1 (mIDH-1)
US11738018B2 (en) 2018-05-16 2023-08-29 FORMA Therapeuetics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
WO2019222551A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
US20210196701A1 (en) * 2018-05-16 2021-07-01 Forma Therapeutics, Inc. Inhibiting mutant idh-1
US11497743B2 (en) 2018-05-16 2022-11-15 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
TW202104207A (zh) * 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
US11566013B1 (en) * 2019-11-20 2023-01-31 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH1)
CN112321571B (zh) * 2020-10-27 2022-06-03 浙江工业大学 2-呋喃-喹啉-4-甲酰胺类化合物及其应用
CN112341389B (zh) * 2020-10-27 2022-07-29 浙江工业大学 一种含氮芳杂环取代的喹啉甲酰胺类衍生物及其应用
CN115850240B (zh) * 2022-12-28 2023-09-19 北京康立生医药技术开发有限公司 一种治疗急性髓系白血病药物奥卢他西尼的合成方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011072174A1 (en) 2009-12-09 2011-06-16 Agios Pharmaceuticals, Inc. Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation
WO2013102431A1 (en) 2012-01-06 2013-07-11 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2014141153A1 (en) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99731A0 (en) 1990-10-18 1992-08-18 Merck & Co Inc Hydroxylated pyridine derivatives,their preparation and pharmaceutical compositions containing them
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US20030105124A1 (en) 2000-04-27 2003-06-05 Susan Beth Sobolov-Jaynes Substituted benzolactam compounds
AU2003243497A1 (en) 2002-06-12 2003-12-31 Millennium Pharmaceuticals, Inc. Antagonists of melanin concentrating hormone receptor
AU2003284399A1 (en) 2002-11-14 2004-06-03 Kyowa Hakko Kogyo Co., Ltd. Plk inhibitors
RU2284325C2 (ru) * 2003-12-17 2006-09-27 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Производные фенил-3-аминометил-хинолона-2 в качестве ингибиторов no-синтетазы, способ их получения, биологически активные соединения и фармацевтическая композиция на их основе
WO2005095382A1 (ja) 2004-03-30 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. 抗腫瘍剤
WO2006054912A1 (fr) 2004-11-18 2006-05-26 Obchestvo S Ogranichennoy Otvetstvennost'u 'asineks Medhim' Derives d'aryl(hetaryl)-3-aminomethylchinolone-2 utilises en tant qu'inhibiteurs de no-synthetase et de cyclo-oxygenase-2, procedes de leur fabrication et compositions pharmaceutiques sur leur base
TW200803855A (en) 2006-02-24 2008-01-16 Kalypsys Inc Quinolones useful as inducible nitric oxide synthase inhibitors
CA2657287A1 (en) * 2006-07-17 2008-01-24 Merck & Co., Inc. 1-hydroxy naphthyridine compounds as anti-hiv agents
JP2010043004A (ja) 2006-12-06 2010-02-25 Dainippon Sumitomo Pharma Co Ltd 新規２環性複素環化合物
EP2152676B1 (en) 2007-04-30 2013-04-03 ProMetic BioSciences Inc. "triazine derivatives, compositions containing such derivatives, and methods of treatment of cancer and autoimmune diseases using such derivatives"
US20120238576A1 (en) 2009-06-08 2012-09-20 California Capital Equity, Llc Triazine Derivatives and their Therapeutical Applications
WO2012006104A2 (en) 2010-06-28 2012-01-12 Academia Sinica, Taiwan Compounds and methods for treating tuberculosis infection
CN102558049B (zh) 2010-12-17 2015-02-04 中国科学院上海药物研究所 一类双香豆素类化合物及其制备方法和用途
US20120184562A1 (en) 2011-01-19 2012-07-19 Kin-Chun Luk 1,6- and 1,8-naphthyridines
US20120184548A1 (en) 2011-01-19 2012-07-19 Romyr Dominique Carboxylic acid aryl amides
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN103814020B (zh) * 2011-06-17 2017-07-14 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
AU2012313888B2 (en) 2011-09-27 2016-03-31 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
US9353121B2 (en) 2011-12-21 2016-05-31 The Regents Of The University Of Colorado, A Body Corporate Anti-cancer compounds targeting Ral GTPases and methods of using the same
US10478445B2 (en) 2013-07-03 2019-11-19 Georgetown University Boronic acid derivatives of resveratrol for activating deacetylase enzymes
BR112016018604A2 (pt) 2014-02-11 2017-08-08 Bayer Pharma AG Benzimidazol-2-aminas como inibidores de midh1
MX372964B (es) 2014-09-19 2020-03-27 Forma Therapeutics Inc Derivados de fenil quinolinona como inhibidores de isocitrato deshidrogenasa mutante (mt-idh)
AU2015317321B2 (en) 2014-09-19 2020-03-12 Forma Therapeutics, Inc. Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
EP3201185B1 (en) 2014-09-19 2018-11-21 Forma Therapeutics, Inc. Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
KR102209667B1 (ko) * 2014-09-19 2021-01-29 포르마 세라퓨틱스 인크. 돌연변이-아이소시트레이트 탈수소효소 저해제로서의 피리딘-2(1h)-온 퀴놀린 유도체
CN107428690B (zh) 2014-12-22 2021-04-13 美国政府健康及人类服务部 可用于治疗癌症的突变idh1抑制剂
GB2533925A (en) 2014-12-31 2016-07-13 Univ Bath Antimicrobial compounds, compositions and methods
WO2016171755A1 (en) 2015-04-21 2016-10-27 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
US9624216B2 (en) 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
JP6473270B2 (ja) 2015-07-27 2019-02-20 イーライ リリー アンド カンパニー ７−フェニルエチルアミノ−４ｈ−ピリミド［４，５−ｄ］［１，３］オキサジン−２−オン化合物及び変異体ｉｄｈ１阻害剤としてのそれらの使用
WO2017146795A1 (en) 2016-02-26 2017-08-31 Agios Pharmaceuticals, Inc. Idh1 inhibitors for the treatment of haematological malignancies and solid tumours
ES2814290T3 (es) 2016-06-06 2021-03-26 Lilly Co Eli Inhibidores de IDH1 mutante
WO2017223202A1 (en) 2016-06-22 2017-12-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thiazole derivatives useful as mutant idh1 inhibitors for treating cancer
PH12019501328B1 (en) 2016-12-16 2023-05-12 Lilly Co Eli 7-phenylethlamino-4h-pyrimido][4,5-d][1,3] oxazin-2-one compounds as mutant 1dh1 and 1dh2 inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011072174A1 (en) 2009-12-09 2011-06-16 Agios Pharmaceuticals, Inc. Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation
WO2013102431A1 (en) 2012-01-06 2013-07-11 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2014141153A1 (en) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh

Also Published As

Publication number Publication date
CN107001328A (zh) 2017-08-01
AU2021215141B2 (en) 2023-10-19
CN111909130A (zh) 2020-11-10
WO2016044789A1 (en) 2016-03-24
CN117695280A (zh) 2024-03-15
EP3194376B1 (en) 2018-10-24
US20200223822A1 (en) 2020-07-16
DK3194376T3 (en) 2019-01-21
TWI686390B (zh) 2020-03-01
PL3194376T3 (pl) 2019-05-31
SMT201900018T1 (it) 2019-02-28
DK3447050T3 (da) 2020-03-09
EP3194376A1 (en) 2017-07-26
PE20171056A1 (es) 2017-07-21
SA517381129B1 (ar) 2021-04-26
MA53352A (fr) 2021-09-15
NZ730373A (en) 2019-11-29
CY1122865T1 (el) 2021-05-05
EP3733662A1 (en) 2020-11-04
SI3447050T1 (sl) 2020-08-31
MX385512B (es) 2025-03-18
CA2961817C (en) 2024-03-12
IL292608A (en) 2022-07-01
CN111909130B (zh) 2023-10-31
PT3733662T (pt) 2023-08-18
AU2019283765A1 (en) 2020-01-16
BR112017005238A2 (pt) 2017-12-19
NZ758641A (en) 2023-12-22
EP3733662B1 (en) 2023-06-07
PH12017500517B1 (en) 2022-08-03
ES2704897T3 (es) 2019-03-20
ZA201902446B (en) 2023-12-20
EP4257131A2 (en) 2023-10-11
JP2017528487A (ja) 2017-09-28
AU2021215141A1 (en) 2021-09-02
MY197533A (en) 2023-06-21
CA2961817A1 (en) 2016-03-24
IL292608B2 (en) 2024-10-01
EA201790657A1 (ru) 2017-08-31
ES2790640T3 (es) 2020-10-28
US20240150319A1 (en) 2024-05-09
SMT202000212T1 (it) 2020-05-08
LT3447050T (lt) 2020-05-11
EP3447050B1 (en) 2020-02-19
BR112017005238B1 (pt) 2023-01-17
AU2015317329A1 (en) 2017-04-27
SG11201702194SA (en) 2017-04-27
IL251163B (en) 2021-05-31
LT3194376T (lt) 2019-02-25
MX2017003404A (es) 2017-07-28
PL3447050T3 (pl) 2020-07-27
ZA202304409B (en) 2024-08-28
ZA201702127B (en) 2019-06-26
ECSP17022933A (es) 2017-08-31
US20170174658A1 (en) 2017-06-22
US10550098B2 (en) 2020-02-04
US10414752B2 (en) 2019-09-17
SI3194376T1 (sl) 2019-03-29
TW201617335A (zh) 2016-05-16
RS60140B1 (sr) 2020-05-29
EP3447050A1 (en) 2019-02-27
PL3733662T3 (pl) 2024-01-22
CL2017000658A1 (es) 2017-12-22
IL282363B (en) 2022-06-01
AU2015317329B2 (en) 2019-10-31
US20160083366A1 (en) 2016-03-24
US20230125739A1 (en) 2023-04-27
HUE041460T2 (hu) 2019-05-28
US20180312487A1 (en) 2018-11-01
CN107001328B (zh) 2020-06-05
HUE062424T2 (hu) 2023-11-28
CO2017003241A2 (es) 2017-09-20
IL292608B1 (en) 2024-06-01
JP6648115B2 (ja) 2020-02-14
KR20170063742A (ko) 2017-06-08
US20210078973A1 (en) 2021-03-18
ME03776B (me) 2021-04-20
US20190263778A1 (en) 2019-08-29
EA201790657A8 (ru) 2018-02-28
MA40481A (fr) 2017-07-26
EP4257131A3 (en) 2024-01-10
US11498913B2 (en) 2022-11-15
MY176250A (en) 2020-07-24
RS58184B1 (sr) 2019-03-29
US9834539B2 (en) 2017-12-05
US12275715B2 (en) 2025-04-15
EA034336B1 (ru) 2020-01-29
ES2953347T3 (es) 2023-11-10
AU2019283765B2 (en) 2021-05-13
US10889567B2 (en) 2021-01-12
CY1121149T1 (el) 2020-05-29
MX2019013203A (es) 2020-01-20
IL251163A0 (en) 2017-04-30
FI3733662T3 (fi) 2023-08-09
PH12017500517A1 (en) 2017-08-07
PT3447050T (pt) 2020-09-17
IL282363A (en) 2021-06-30
HRP20200666T1 (hr) 2020-07-24
PT3194376T (pt) 2019-02-04

Similar Documents

Publication Publication Date Title
US12275715B2 (en) Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
JP6751081B2 (ja) 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのピリジニルキノリノン誘導体
JP2017528489A (ja) 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのフェニルキノリノン誘導体
HK40102356A (en) Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
HK40033589B (en) Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
HK40033589A (en) Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
HK40002980B (en) Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
HK40002980A (en) Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
HK1241376A1 (en) Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
HK1241376B (en) Pyridin-2(1h)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 6